RecruitingRecruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571 · Immunome, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1 Study of IM-1617 in Participants With Advanced Malignancies
About this study
This is a Phase 1 open-label, multicenter, dose escalation and expansion study designed to determine the safety, tolerability, PK, and preliminary antitumor activity of IM-1617 administered to participants with unresectable locally advanced or metastatic solid tumors. The study consists of 2 parts:
Part A: A dose-escalation phase to evaluate the safety and tolerability of IM-1617 to determine the recommended dose for expansion (RDE), evaluate maximum tolerated dose, and maximum achievable dose of IM-1617.
Part B: An expansion phase to further evaluate the safety and preliminary antitumor activity of IM-1617 monotherapy at the RDE and one or more other dose regimens in up to 4 indication-specific cohorts.
Eligibility criteria
Inclusion Criteria:
1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
2. Part A: Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:
* CRC, all subtypes
* NSCLC:
* Non-squamous cell carcinoma subtypes, such as adenocarcinoma
* Squamous cell carcinoma subtype
* Breast cancer (subtypes based on estrogen/progesterone receptor and HER2 testing according to American Society of Clinical Oncology - College of American Pathologists guidelines):
* Triple-negative breast cancer
* HR+, HER2- subtype
* Esophageal, esophagogastric junction, and gastric cancer:
* Adenocarcinoma subtype
* Other histologies, if approved by the Medical Monitor, which may include: head and neck squamous cell carcinoma; cervical cancer; bladder cancer; squamous cell carcinoma subtype of esophageal, esophagogastric junction, and gastric cancer; HER2+ breast cancer
3. Part B Cohorts - Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:
* Cohort B1: CRC, all subtypes
* Cohort B2: NSCLC
* Non-squamous cell carcinoma subtypes, such as adenocarcinoma
* Squamous cell carcinoma subtype
* Cohorts B3 and B4: Cohort-specific disease indications may include those listed for Part A
4. Participants must have disease that is considered to be noncurative and meet the appropriate criteria below:
* Part A only: Participants have progressed on, were intolerant to, or have a contraindication to prior SOC treatments, with no satisfactory SOC treatment options available.
* Part B only:
* Cohort B1 (CRC):
* Participants must have previously progressed on, were intolerant to, or have a contraindication to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, bevacizumab, and for those with RAS wild-type tumors, an anti-epidermal growth factor receptor (EGFR)-directed monoclonal antibody in advanced disease setting.
* Participants with actionable biomarkers must have been treated with at least one prior appropriate biomarker-directed therapy.
* If any of these therapies were given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.
* Participants must not have received more than 3 prior lines of systemic therapy (excluding targeted therapies for actionable biomarkers).
* Cohort B2 (NSCLC):
* Participants must have previously progressed on, were intolerant to, or have a contraindication to platinum-based chemotherapy and a programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibody (given concurrently or sequentially with chemotherapy) in advanced disease setting.
* Participants with actionable biomarkers must have been treated with at least one prior appropriate targeted therapy.
* If any of these therapies were given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.
* Participants must not have received more than 2 prior lines of systemic therapy (excluding targeted therapies for actionable biomarkers).
* Cohorts B3 and B4: Criteria will be specified based on the disease indications selected.
5. Participants must have measurable disease as defined per RECIST v1.1
Exclusion Criteria:
1. Previously treated with an antibody-drug conjugate (ADC) with a topoisomerase-1 (TOP1) inhibitor payload. Exception: Participants with NSCLC or breast cancer may have received up to one prior ADC with a TOP1 inhibitor payload
2. History of anaphylactic reaction to TOP1 inhibitors (e.g., irinotecan) or TOP1 inhibiting ADCs
3. Life expectancy \< 12 weeks
4. Prior solid organ transplant
5. Symptomatic ascites or pleural effusion
6. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
7. Known history of another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone definitive/curative therapy, has had no evidence of recurrence and has negligible risk of metastatic disease of death, with approval by the Medical Monitor
Study design
Enrollment target: 200 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-05-21
Estimated completion: 2029-01
Last updated: 2026-11-03
Interventions
Drug: IM-1617
Primary outcomes
- • Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs) (Through 30 days after last dose of study treatment; approximately 12 months)
- • Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of AEs of interest (AEIs) (Through 30 days after last dose of study treatment; approximately 12 months)
- • Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of AEs leading to discontinuation (Through 30 days after last dose of study treatment; approximately 12 months)
Sponsor
Immunome, Inc. · industry
Contacts & investigators
ContactImmunome Medical Monitor · contact · info@immunome.com · 800-811-4074
All locations (5)
Yale Cancer CenterRecruiting
New Haven, Connecticut, United States
Florida Cancer Specialists & Research Institute - Sarasota CattlemenRecruiting
Sarasota, Florida, United States
Massachusetts General HospitalRecruiting
Boston, Massachusetts, United States
MD Anderson Cancer CenterRecruiting
Houston, Texas, United States
NEXT DallasRecruiting
Irving, Texas, United States